caa a22 4500 605491542 CHVBK 20210128100510.0 cr unu---uuuuu 210128e20151001xx s 000 0 eng 10.1007/s10147-015-0800-0 doi (NATIONALLICENCE)springer-10.1007/s10147-015-0800-0 The usefulness of 18F-FDG-PET/CT in discriminating benign from malignant ovarian teratomas [Elektronische Daten] [Takanori Yokoyama, Kazuhiro Takehara, Yasuko Yamamoto, Shinichi Okame, Yuko Shiroyama, Takashi Yokoyama, Takayoshi Nogawa, Yosifumi Sugawara] Background: The present study investigates the usefulness of 18F-FDG-PET/CT (PET/CT) in distinguishing between benign and malignant ovarian teratomas. Methods: This study includes 4 mature teratomas (MTs) with malignant transformation, 8 immature teratomas (ITs), and 16 MTs that were diagnosed after surgical resection. Preoperative tumor marker values, MRI findings, PET/CT SUVmax values, and other clinical parameters were retrospectively compared with those of 14 patients who had MTs. Results: The median CA125 was significantly higher for ITs than for MTs (P=0.04). The median AFP was significantly higher for ITs than for MTs (P=0.0034). The median SUVmax values for MTs with malignant transformation, ITs, and MTs were 18.3 (5.3-23.3), 6.0 (3.6-22.6), and 1.1 (1.0-15.5), respectively. SUVmax was significantly higher in MTs with malignant transformation and ITs than in MTs (P=0.004, P=0.0007). With a cut-off SUVmax of 3.6 to distinguish between benign and malignant MTs, sensitivity was 100%, specificity was 81%, positive predictive value was 80%, negative predictive value was 100%, and diagnostic accuracy was 89% (AUC 0.94). However, one patient with an MT had a high SUVmax corresponding to values in the central nervous system (CNS). Conclusions: 18F-FDG-PET/CT has a high diagnostic accuracy in distinguishing between benign and malignant ovarian teratomas. Thus, PET/CT may be useful in cases where the diagnosis is unclear on MRI and other clinical findings. However, some MTs with abundant CNS tissue may have a high SUVmax. Therefore, the diagnosis of a benign or malignant lesion should be made carefully in conjunction with other clinical findings. Japan Society of Clinical Oncology, 2015 FDG-PET/CT nationallicence SUVmax nationallicence Teratoma nationallicence Malignant transformation nationallicence Immature teratoma nationallicence Yokoyama Takanori Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Takehara Kazuhiro Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Yamamoto Yasuko Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Okame Shinichi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Shiroyama Yuko Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Yokoyama Takashi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Nogawa Takayoshi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut Sugawara Yosifumi Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 960-966 1341-9625 20:5<960 2015 20 10147 https://doi.org/10.1007/s10147-015-0800-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-015-0800-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yokoyama Takanori Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Takehara Kazuhiro Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Yamamoto Yasuko Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Okame Shinichi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Shiroyama Yuko Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Yokoyama Takashi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Nogawa Takayoshi Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 700 1- Sugawara Yosifumi Department of Diagnostic Radiology, National Hospital Organization, Shikoku Cancer Center, Ko-160 Minamiumemoto, 791-0280, Matsuyama, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/5(2015-10-01), 960-966 1341-9625 20:5<960 2015 20 10147